Millennium Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Millennium Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.6M	Sell	232,000 -195,300	-46%	-$24.4M	0.01%	1241
2025 Q4	$52.1M	Sell	427,300 -772,100	-64%	-$88.5M	0.02%	797
2025 Q3	$120M	Buy	1,199,400 +343,700	+40%	+$31M	0.05%	351
2025 Q2	$71M	Buy	855,700 +267,400	+45%	+$21.3M	0.03%	601
2025 Q1	$47.7M	Sell	588,300 -581,000	-50%	-$51.9M	0.03%	804
2024 Q4	$105M	Sell	1,169,300 -515,600	-31%	-$50M	0.05%	376
2024 Q3	$166M	Buy	1,684,900 +44,500	+3%	+$4.37M	0.08%	227
2024 Q2	$152M	Sell	1,640,400 -729,600	-31%	-$65.4M	0.07%	274
2024 Q1	$225M	Buy	2,370,000 +1,072,300	+83%	+$99.5M	0.1%	175
2023 Q4	$116M	Buy	1,297,700 +449,900	+53%	+$33.4M	0.05%	359
2023 Q3	$61.9M	Buy	847,800 +571,800	+207%	+$45.7M	0.03%	576
2023 Q2	$23M	Sell	276,000 -561,800	-67%	-$47M	0.01%	1280
2023 Q1	$63.8M	Buy	837,800 +631,000	+305%	+$52.4M	0.04%	551
2022 Q4	$17.2M	Sell	206,800 -1,612,300	-89%	-$131M	0.01%	1583
2022 Q3	$144M	Sell	1,819,100 -260,200	-13%	-$21.9M	0.09%	191
2022 Q2	$154M	Buy	2,079,300 +814,000	+64%	+$61.1M	0.1%	140
2022 Q1	$114M	Buy	1,265,300 +634,000	+100%	+$58.5M	0.06%	290
2021 Q4	$70.7M	Buy	631,300 +416,300	+194%	+$50.2M	0.04%	534
2021 Q3	$27M	Sell	215,000 -103,100	-32%	-$13.3M	0.02%	1057
2021 Q2	$43.1M	Buy	318,100 +250,700	+372%	+$33M	0.03%	681
2021 Q1	$9.14M	Buy	+67,400	New	+$10.1M	0.01%	1885
2020 Q1	–	Sell	-70,900	Closed	-$6.74M	–	4577
2019 Q4	$6.74M	Hold	70,900	–	–	0.01%	1682
2019 Q3	$5.41M	Buy	70,900 +35,900	+103%	+$2.98M	0.01%	1736
2019 Q2	$3.07M	Hold	35,000	–	–	﹤0.01%	2134
2019 Q1	$3.17M	Buy	+35,000	New	+$2.98M	﹤0.01%	2081
2016 Q4	–	Sell	-100,000	Closed	-$6.63M	–	3793
2016 Q3	$6.63M	Buy	+100,000	New	+$6.19M	0.01%	1164
2016 Q2	–	Sell	-75,000	Closed	-$3.88M	–	3647
2016 Q1	$3.88M	Buy	+75,000	New	+$3.9M	0.01%	1396

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management's XBI Position: Q1 2026 in Review

Millennium Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 273% in Q1 2026, buying an estimated $3.19M and bringing the position to 34,918 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3081.

Millennium Management first reported a position in XBI in Q1 2014 and has held it in 33 quarters since. The position peaked at $89.5M in Q4 2023. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Millennium Management held 34,918 shares of State Street SPDR S&P Biotech ETF worth $4.46M as of Q1 2026.
Millennium Management bought 25,548 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $3.19M.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3081 holding.
Millennium Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and has held it in 33 quarters since.
Millennium Management's State Street SPDR S&P Biotech ETF position peaked at $89.5M in Q4 2023.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.